

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE MEDICINAL PRODUCT**

Rocuronium Kabi 10 mg/ml solution for injection/infusion

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml of solution for injection / infusion contains 10 mg rocuronium bromide.

Each vial with 2.5 ml contains 25 mg rocuronium bromide.

Each vial with 5 ml contains 50 mg rocuronium bromide.

Each vial with 10 ml contains 100 mg rocuronium bromide.

For a full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Solution for injection / infusion

Clear, colourless to pale brownish-yellow solution

pH of the solution: 3.8 to 4.2

Osmolarity: 271– 312 mOsmol/kg.

### **4. CLINICAL PARTICULARS**

#### **4.1 Therapeutic indications**

Rocuronium bromide is indicated as an adjunct to general anaesthesia to facilitate tracheal intubation during routine and rapid sequence induction, to provide skeletal muscle relaxation, during surgery. It is also indicated as an adjunct in the intensive care unit (ICU) (e.g. to facilitate intubation), for short term use.

See also section 4.2 and 5.1.

#### **4.2 Posology and method of administration**

As with other neuromuscular blocking agents, the dosage of rocuronium bromide should be individualised in each patient. The method of anaesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other medicinal products that are administered concomitantly and the condition of the patient should be taken into account when determining the dose. The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of the neuromuscular block and recovery.

Inhalational anaesthetics potentiate the neuromuscular blocking effects of rocuronium bromide. This potentiation becomes clinically relevant during the course of anaesthesia when a certain tissue concentration of the volatile agents is reached. Consequently, adjustments should be made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of

rocuronium bromide during long lasting procedures (longer than 1 hour) under inhalational anaesthesia.

In adult patients the following dosage recommendations may serve as a general guidance for tracheal intubation and muscle relaxation for short to long lasting surgical procedures and for use in the intensive care unit.

This medicinal product is for single use only.

## **Surgical Procedures**

### Tracheal intubation

The standard intubating dose during routine anaesthesia is 0.6 mg rocuronium bromide per kg body weight, which results in adequate intubation conditions within 60 seconds in nearly all patients. A dose of 1.0 mg rocuronium bromide per kg body weight is recommended for facilitating tracheal intubation conditions during rapid sequence induction of anaesthesia, after which adequate intubation conditions are also established within 60 seconds in nearly all patients. If a dose of 0.6 mg rocuronium bromide per kg body weight is used for rapid sequence induction of anaesthesia, it is recommended to intubate the patient 90 seconds after administration of rocuronium bromide.

### Maintenance dosage

The recommended maintenance dose is 0.15 mg rocuronium bromide per kg body weight. In case of long-term inhalational anaesthesia it should be reduced to 0.075 - 0.1 mg of rocuronium bromide per kg body weight.

The maintenance doses should best be given when twitch height has recovered to 25 % of control twitch height, or when 2 to 3 responses to train-of-four stimulation (TOF) are present.

### Continuous infusion

If rocuronium bromide is administered by continuous infusion, it is recommended to give a loading dose of 0.6 mg rocuronium bromide per kg body weight and, when the neuromuscular block starts to recover, to start administration by infusion. The infusion rate should be adjusted to maintain twitch response at 10 % of control twitch height or to maintain 1 to 2 responses to train-of-four stimulation.

In adults under intravenous anaesthesia, the infusion rate required to maintain the neuromuscular block at this level ranges from 0.3 - 0.6 mg/kg/h. Under inhalational anaesthesia the infusion rate ranges from 0.3 - 0.4 mg/kg/h.

Continuous monitoring of the neuromuscular block is essential since infusion rate requirements vary from patient to patient and with the anaesthetic method used.

### Dosage in pregnant patients

In patients undergoing Caesarean section, it is recommended to only use a dose of 0.6 mg rocuronium bromide per kg body weight, since a 1.0 mg/kg dose has not been investigated in this patient group.

Reversal of neuromuscular block induced by neuromuscular blocking agents may be inhibited or unsatisfactory in patients receiving magnesium salts for toxemia of pregnancy because magnesium salts enhance neuromuscular blockade. Therefore, in these patients the dosage of rocuronium should be reduced and be titrated to twitch response.

#### Dosage in paediatric patients

For infants (28 days-23 months) children (2-11 years) and adolescents (12-17 years) the recommended intubation dose during routine anaesthesia and maintenance dose are similar to those in adults. For continuous infusion in pediatrics, the infusion rates, with exception of children, are the same as for adults. For children higher infusion rates might be necessary.

For children the same initial infusion rates as for adults are recommended and this should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 or 2 responses to train-of-four stimulation during the procedure.

The experience with rocuronium bromide in rapid sequence induction in pediatric patients is limited. Rocuronium bromide is therefore not recommended for facilitation tracheal intubation conditions during rapid sequence induction in pediatric patients.

There are no data to support recommendations for the use of rocuronium bromide in new-born infants (0 -1 month).

#### Dosage in geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure

The standard intubation dose for geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure during routine anaesthesia is 0.6 mg rocuronium bromide per kg body weight. A dose of 0.6 mg per kg body weight should be considered for rapid sequence induction of anaesthesia in patients in which a prolonged duration of action is expected however adequate conditions for intubation may not be established for 90 seconds after administration of rocuronium bromide. Regardless of the anaesthetic technique used, the recommended maintenance dose for these patients is 0.075 - 0.1 mg rocuronium bromide per kg body weight, and the recommended infusion rate is 0.3 - 0.4 mg/kg/h (see also Continuous infusion).

#### Dosage in overweight and obese patients

When used in overweight or obese patients (defined as patients with a body weight of 30 % or more above ideal body weight) doses should be reduced taking into account a lean body mass.

### **Intensive care procedures**

#### Tracheal intubation

For tracheal intubation, the same doses should be used as described above under surgical procedures.

### **Administration**

Rocuronium bromide is administered intravenously (i.v.) either as a bolus injection or as a continuous infusion (for further information see also section 6.6).

### **4.3 Contraindications**

Rocuronium bromide is contra-indicated in patients with hypersensitivity to rocuronium bromide or to the bromide ion or to any of the excipients.

#### **4.4 Special warnings and precautions for use**

Rocuronium bromide should be administered only by an experienced staff familiar with the use of neuromuscular blocking agents. Adequate facilities and staff for endotracheal intubation and artificial ventilation have to be available for immediate use.

Since rocuronium bromide causes paralysis of the respiratory muscles, ventilatory support is mandatory for patients treated with this active substance until adequate spontaneous respiration is restored. As with all neuromuscular blocking agents, it is important to anticipate intubation difficulties, particularly when used as part of a rapid sequence induction technique.

As with other neuromuscular blocking agents, residual curarization has been reported for Rocuronium. In order to prevent complications resulting from residual curarization, it is recommended to extubate only after the patient has recovered sufficiently from neuromuscular block. Other factors which could cause residual curarization after extubation in the post-operative phase (such as drug interactions or patient condition) should also be considered. If not used as part of standard clinical practice, the use of a reversal agent should be considered, especially in those cases where residual curarization is more likely to occur.

It is essential to ensure that the patient is breathing spontaneously, deeply and regularly before leaving the theatre after anaesthesia.

Anaphylactic reactions (see above) can occur after the administration of neuromuscular blocking agents. Precautions for treating such reactions should always be taken. Particularly in the case of previous anaphylactic reactions to neuromuscular blocking agents, special precautions should be taken since allergic cross-reactivity to neuromuscular blocking agents has been reported.

Dose levels higher than 0.9 mg rocuronium bromide per kg body weight may increase the heart rate; this effect could counteract the bradycardia produced by other anaesthetic agents or by vagal stimulation.

In general, following long term use of muscle relaxants in the ICU, prolonged paralysis and/or skeletal muscle weakness has been noted. In order to help preclude possible prolongation of neuromuscular blockage and/or overdose, it is strongly recommended that neuromuscular transmission is monitored throughout the use of muscle relaxants. In addition, patients should receive adequate analgesia and sedation. Furthermore, muscle relaxants should be titrated to the effect in the individual patient. This should be done by or under the supervision of experienced clinicians who are familiar with the effects and with appropriate neuromuscular monitoring techniques.

Because rocuronium bromide is always used with other agents and because of the possibility of the occurrence of malignant hyperthermia during anaesthesia, even in the absence of known triggering agents, clinicians should be familiar with the early signs, confirmatory diagnosis and treatment of malignant hyperthermia prior to the start of any anaesthesia. In animal studies it was shown that rocuronium bromide is not a triggering factor for malignant hyperthermia.

Myopathy has been reported after long-term concurrent use of non-depolarising neuromuscular blockers and corticosteroids. The co-administration period should be reduced to be as short as possible (see section 4.5).

Rocuronium should only be administered after full recovery from the neuromuscular blockade caused by suxamethonium.

The following conditions may influence the pharmacokinetics and/or pharmacodynamics of rocuronium bromide:

Hepatic and/or biliary tract disease and renal failure

Rocuronium bromide is excreted in urine and bile. Therefore, it should be used with caution in patients with clinically significant hepatic and/or biliary diseases and/or renal failure. In these patient groups prolongation of the effect has been observed with doses of 0.6 mg rocuronium bromide per kg body weight.

Prolonged circulation time

Conditions associated with prolonged circulation time such as cardiovascular diseases, old age and an oedematous state resulting in an increased volume of distribution, may contribute to a slower onset of the effect.

Neuromuscular disease

Like other neuromuscular blocking agents, rocuronium bromide should be used with extreme caution in patients with a neuromuscular disease or after poliomyelitis since the response to neuromuscular blocking agents may be considerably altered in these cases. The magnitude and direction of this alteration may vary widely. In patients with myasthenia gravis or with the myasthenic (Eaton-Lambert) syndrome, small doses of rocuronium bromide may have profound effects and rocuronium bromide should be titrated to the response.

Hypothermia

In surgery under hypothermic conditions, the neuromuscular blocking effect of rocuronium bromide is increased and the duration prolonged.

Obesity

Like other neuromuscular blocking agents, rocuronium bromide may exhibit a prolonged duration and a prolonged spontaneous recovery in obese patients, when the administered doses are calculated on actual body weight. Burns  
Patients with burns are known to develop resistance to non-depolarizing neuromuscular blocking agents. It is recommended that the dose is titrated to the response.

Conditions which may increase the effects of rocuronium bromide

Hypokalaemia (e.g. after severe vomiting, diarrhoea or diuretic therapy), hypermagnesaemia, hypocalcaemia (after massive transfusions), hypoproteinaemia, dehydration, acidosis, hypercapnia and cachexia. Severe electrolyte disturbances, altered blood pH or dehydration should therefore be corrected when possible.

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

The following medicinal products have been shown to influence the magnitude and/or duration of the effect of non-depolarizing neuromuscular blocking agents:

##### Increased effect

- Halogenated volatile anaesthetics
- High doses of: thiopental, methohexital, ketamine, fentanyl, gammahydroxybutyrate, etomidate and propofol
- Other non-depolarizing neuromuscular blocking agents.
- Prior administration of suxamethonium (see section 4.4).
- Long term concomitant use of corticosteroids and Rocuronium in the ICU may result in prolonged duration of neuromuscular block or myopathy (see sections 4.4 and 4.8).

##### Other medicinal products

- Antibiotics: aminoglycosides, lincosamides (e.g. lincomycin and clindamycin), polypeptide antibiotics, acylamino-penicillin antibiotics, tetracyclines, high doses of metronidazole.
- diuretics, thiamine, MAO inhibiting agents, quinidine and its isomer quinine, protamine, adrenergic blocking agents, magnesium salts, calcium channel blocking agents and lithium salts and local anaesthetics (lidocaine i.v., bupivacaine epidural).

##### Decreased effect

- Neostigmine, edrophonium, pyridostigmine, aminopyridine derivatives
- Prior chronic administration of corticosteroids, phenytoin or carbamazepine
- Noradrenaline, azathioprine (only transient and limited effect), theophylline, calcium chloride, potassium chloride
- protease inhibitors

##### Variable effect

Administration of other non-depolarizing neuromuscular blocking agents in combination with rocuronium bromide may produce attenuation or potentiation of the neuromuscular block, depending on the order of administration and the neuromuscular blocking agent used.

Suxamethonium given after the administration of rocuronium bromide may produce potentiation or attenuation of the neuromuscular blocking effect of rocuronium bromide.

##### Effect of rocuronium on other drugs

Combined use with lidocaine could result in a more instant effect of lidocaine.

Recurarization has been reported after post-operative administration of: aminoglycoside, lincosamide, polypeptide and acylamino-penicillin antibiotics, quinidine, quinine and magnesium salts (see section 4.4).

#### 4.6 Pregnancy and lactation

##### Pregnancy

There are very limited data on the use of rocuronium bromide during human pregnancy. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Rocuronium bromide should only be given to pregnant women when strictly necessary and the attending physician decides that the benefits outweigh the risks. Use of rocuronium bromide during caesarean section at doses of 0.6 mg/kg bodyweight does not effect the Apgar score, the foetal muscle tone or the cardiorespiratory adaptation.

From umbilical cord blood sampling it is apparent that only limited placental transfer of rocuronium bromide occurs, which does not lead to the observation of clinical adverse reactions in the new-born infant.

Note: doses of 1.0 mg/kg have been investigated during rapid sequence induction of anaesthesia, but not in Caesarean section patients.

##### Lactation

There are no human data on the use of rocuronium bromide during lactation. Other medicinal products of this class show little excretion into breast milk and low resorption by the suckling child. Animal studies have shown excretion of rocuronium bromide in insignificant amounts in breast milk.

A decision on whether to continue/discontinue breast-feeding should be made taking into account the benefit of breast-feeding and the potential risk to the child.

#### 4.7 Effects on ability to drive and use machines

Rocuronium bromide has a major influence on the ability to drive and use machines. It is not recommended to use potentially dangerous machinery or to drive a car during the first 24 hours after the full recovery from the neuromuscular blocking action of rocuronium bromide.

#### 4.8 Undesirable effects

The frequency of undesirable effects is classified into the following categories:

<b>Very common</b>	≥ 1/10
<b>Common</b>	≥ 1/100 to < 1/10
<b>Uncommon</b>	≥ 1/1,000 to < 1/100
<b>Rare</b>	≥ 1/10,000 to < 1/1,000
<b>Very rare</b>	< 1/10,000
<b>Not known</b>	cannot be estimated from the available data

The most common undesirable effects are pain/reaction around injection site, changes in vital functions and prolonged neuromuscular block.

**Immune system disorders**Very rare

- Anaphylactic reaction e.g. anaphylactic shock
- Anaphylactoid reaction\*
- Hypersensitivity

**Nervous system disorders**Very rare

- Paralysis

**Cardiac disorders**Very rare

- Tachycardia

**Vascular disorders**Very rare

- Hypotension
- Circulatory collapse and shock

**Respiratory, thoracic, and mediastinal disorders**Very rare

- Bronchospasm

Not known

- Apnoea
- Respiratory failure

**Skin and subcutaneous tissue disorders**Very rare

- Rash, erythematous rash
- Angioedema
- Urticaria
- Itching
- Exanthema

**Musculoskeletal disorders**Not known

- skeletal muscle weakness
- steroid myopathy \* (see section 4.4)

**General disorders and administration site conditions**Very common

- Injection site pain/reaction\*

**Investigations**Very rare

- Increased histamine level\*

**Injury, poisoning and procedural complication**Very rare

- Prolonged neuromuscular block\*



### **\*Additional information on adverse reactions:**

#### **Anaphylactic reaction**

Severe anaphylactic reactions to neuromuscular blocking agents have been reported to be fatal in some cases. Due to the possible severity of these reactions, one should always assume that they may occur and take the necessary precautions.

#### **Local injection site reactions**

During rapid sequence induction of anaesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. In clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anaesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anaesthesia with fentanyl and thiopental.

#### **Increased histamine level**

Since neuromuscular blocking agents are known to be capable of inducing histamine release both locally and systemically, the possible occurrence of itching and erythematous reaction at the site of injection and/or generalised histaminoid (anaphylactoid) reactions such as bronchospasm and cardiovascular changes e.g. hypotension and tachycardia should always be taken into consideration when administering these drugs. Rash, exanthema, urticaria, bronchospasm and hypotension have been reported very rarely in patients given rocuronium bromide.

In clinical studies only a slight increase in mean plasma histamine level has been observed following rapid bolus administration of 0.3 - 0.9 mg rocuronium bromide per kg body weight.

#### **Prolonged neuromuscular block**

The most frequent adverse reaction to non-depolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. This may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.

### **4.9 Overdose**

In the event of overdose and prolonged neuromuscular block, the patient should continue to receive ventilatory support and sedation. Upon start of spontaneous recovery an acetylcholinesterase inhibitor (e.g. neostigmine, edrophonium, pyridostigmine) should be administered in adequate doses. When administration of an acetylcholinesterase inhibiting agent fails to reverse the neuromuscular effects of rocuronium bromide, artificial ventilation must be continued until spontaneous breathing is restored. Repeated dosages of an acetylcholinesterase inhibitor can be dangerous.

In animal studies, severe depression of cardiovascular function, ultimately leading to cardiac collapse, did not occur until a cumulative dose of 750 x ED<sub>90</sub> (135 mg per kg body weight) was administered.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: muscle relaxants, peripherally acting agents, other quaternary ammonium compounds.

ATC code: M03AC09

#### Pharmacodynamics

Rocuronium bromide is an intermediate acting, non-depolarizing neuromuscular blocking agent with a fast onset, possessing all of the characteristic pharmacological actions of this class of medicinal products (curariform). It acts by competing for nicotinic cholinergic receptors at the motor end-plate. This action is antagonised by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine.

The ED<sub>90</sub> (dose required to produce 90 % depression of the twitch response of the thumb to stimulation of the ulnar nerve) during balanced anaesthesia is approximately 0.3 mg per kg body weight.

#### Routine practice

Within 60 seconds after intravenous administration of a dose of 0.6 mg rocuronium bromide per kg body weight (2 x ED<sub>90</sub> under balanced anaesthesia), adequate intubation conditions can be achieved in nearly all patients. In 80 % of these patients intubation conditions are rated excellent. Within 2 minutes general muscle paralysis adequate for any type of procedure is established. The clinical duration (the duration until spontaneous recovery to 25% of control twitch height) with this dose is 30 - 40 minutes. The total duration (time until spontaneous recovery to 90% of control twitch height) is 50 minutes. The mean time of spontaneous recovery of twitch response from 25 to 75 % (recovery index) after a bolus dose of 0.6 mg rocuronium bromide per kg body weight is 14 minutes.

With lower dosages of 0.3 - 0.45 mg rocuronium bromide per kg body weight (1 - 1 ½ x 2 x ED<sub>90</sub>), the onset of the effect is slower and the duration of action is shorter (13 - 26 min). After administration of 0.45 mg rocuronium bromide per kg body weight, acceptable intubation conditions are reached after 90 seconds.

#### Emergency intubation

During rapid sequence induction of anaesthesia under propofol or fentanyl/thiopental anaesthesia, adequate intubation conditions are achieved within 60 seconds in 93 % and 96 % of the patients respectively, after administration of a dose of 1.0 mg rocuronium bromide per kg body weight. Of these, 70 % are rated excellent. The clinical duration with this dose approaches 1 hour, at which time the neuromuscular block can be safely reversed

After administration of a dose of 0.6 mg rocuronium bromide per kg body weight, adequate intubation conditions are achieved within 60 seconds in 81 % and 75 % of the patients during a rapid sequence induction technique with propofol or fentanyl/thiopental, respectively.

Doses higher than 1.0 mg rocuronium bromide per kg body weight will not improve the intubation conditions appreciably; the duration of the effect, however, will be prolonged. Doses higher than 4 x ED<sub>90</sub> have not been studied.

### Intensive care

The use of rocuronium in the Intensive Care Unit was studied in two open-label trials. A total of 95 adult patients were treated with an initial dose of 0.6 mg rocuronium bromide per kg body weight, followed by a continuous infusion of 0.2 - 0.5 mg/kg/h during the first hour of administration as soon as twitch height recovers to 10 % or upon reappearance of 1 to 2 twitches to train-of-four (TOF) stimulation. The dosages were individually titrated. In the following hours, doses were decreased under regular monitoring of the TOF stimulation. Administration for a time period of up to 7 days has been investigated.

Adequate neuromuscular blockade was achieved, but a high variability in hourly infusion rates between patients and a prolonged recovery from neuromuscular blockade was observed.

The time to recover of the train of four ratio to 0.7 is not significantly correlated to the total duration of rocuronium infusion. After a continuous infusion for 20 hours or more the median (range) time between return of T2 to train of four stimulation and recovery of the train of four ratio to 0.7 varied between 0,8 and 12,5 hours in patients without multiple organ failure and 1.2 - 25.5 hours in patients with multiple organ failure.

### Special populations

The mean time to effect after 0.6 mg/kg is shorter in infants and children compared to adults. The duration of effect is shorter in children compared to adults.

The duration of the effect of maintenance doses of 0.15 mg rocuronium bromide per kg body weight might be somewhat longer under enflurane and isoflurane anaesthesia in geriatric patients and in patients with hepatic or renal disease (approximately 20 minutes) than in patients without impairment of excretory organ functions under intravenous anaesthesia (approximately 13 minutes). No cumulation of effect (progressive increase in duration of action) with repetitive maintenance doses at the recommended level has been observed.

### Cardiovascular surgery

In patients scheduled for cardiovascular surgery the most common cardiovascular changes during the onset of maximum blockage after receiving a dose of 0.6 - 0.9 mg rocuronium bromide per kg body weight are a slight and clinically insignificant increase in heart rate up to 9% and an increase in mean arterial blood pressure up to 16% from the control values.

### Antagonists

Administration of acetylcholinesterase inhibitors, such as neostigmine, pyridostigmine or edrophonium, antagonises the action of rocuronium bromide.

## 5.2 Pharmacokinetic properties

After intravenous administration of a single bolus dose of rocuronium bromide, the time course of the plasma concentration runs in three exponential phases. In normal adults, the mean (95%CI) elimination half-life is 73 (66-80) minutes, the (apparent) volume of distribution at steady state conditions is 203 (193-214) ml/kg and the plasma clearance is 3.7 (3.5-3.9) ml/kg/min.

The plasma clearance in geriatric patients and in patients with renal dysfunction is slightly reduced compared to younger patients with normal renal function. In patients with hepatic diseases, the mean elimination half-life is prolonged by 30 minutes and the mean plasma clearance is reduced by 1 ml/kg/min . (See also section 4.2).

The apparent volume of distribution in infants (3–12 months) is higher compared to older children (1–8 years) and adults. In children aged 3-8 years, clearance is higher and the elimination half-life is approximately 20 minutes shorter compared to adults and children < 3 years.

When administered as a continuous infusion to facilitate mechanical ventilation for a time period of 20 hours or more, the mean elimination half-life and the mean (apparent) volume of distribution at steady state are increased. A high variability between patients was found in controlled clinical studies, related to the nature and extent of (multiple) organ failure and individual patient characteristics. In patients with multiple organ failure a mean ( $\pm$ SD) elimination half-life of 21.5 ( $\pm$ 3.3) hours, an (apparent) volume of distribution at steady state of 1.5 ( $\pm$ 0.8) l/kg and a plasma clearance of 2.1 ( $\pm$ 0.8) ml/kg/min were found.

Rocuronium bromide is excreted in urine and bile. Excretion in urine approaches 40 % within 12 - 24 hours. After injection of a radiolabeled dose of rocuronium bromide, excretion of the radiolabel is on average 47 % in urine and 43 % in faeces after 9 days. Approximately 50 % is recovered as rocuronium bromide. No metabolites are detected in the plasma.

## 5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction and genotoxicity.

Carcinogenicity studies have not been performed with rocuronium bromide.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Water for injections  
Acetic acid, glacial (for pH-adjustment)  
Sodium chloride  
Sodium acetate trihydrate

## 6.2 Incompatibilities

Physical incompatibility has been documented for rocuronium bromide when added to solutions containing the following active substances: amphotericin, amoxicillin, azathioprine, cefazolin, cloxacillin, dexamethasone, diazepam, enoximone, erythromycin, famotidine, furosemide, hydrocortisone sodium succinate, insulin, intralipid, methohexital, methylprednisolone, prednisolone sodium succinate, thiopental, trimethoprim and vancomycin.

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

## 6.3 Shelf life

### Unopened vial

3 years

### Opened vial

The product should be used immediately after opening the vial.

### After dilution

Chemical and physical in-use stability of a 5.0 mg/ml and 0.1 mg/ml solution (diluted with sodium chloride 9 mg/ml (0.9%) and glucose 50 mg/ml (5%) solution for infusion) has been demonstrated for 24 hours at room temperature exposed to room light in glass, PE and PVC.

From the microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

## 6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C).

### Storage out of the refrigerator:

Rocuronium Kabi may also be stored outside of the refrigerator at a temperature of up to 30°C for a maximum of 12 weeks, after which it should be discarded. The product should not be placed back into the refrigerator, once it has been kept outside. The storage period must not exceed the shelf-life.

For storage conditions of the diluted medicinal product, see section 6.3.

## 6.5 Nature and contents of container

Colourless glass vials (type I) with chlorobutyl rubber stopper and aluminium cap. Content of the vials: 2.5 ml, 5 ml or 10 ml.

### Package sizes:

Packaging of 5 and 10 vials each containing 2.5 ml.

Packaging of 5 and 10 vials each containing 5 ml.

Packaging of 5 and 10 vials each containing 10 ml.

Not all pack sizes may be marketed.

## **6.6 PECIAL precautions for disposal and other handling**

Any unused solutions should be discarded.

The solution is to be visually inspected prior to use. Only clear solutions practically free from particles should be used.

Rocuronium Kabi has shown to be compatible with: sodium chloride 9 mg/ml (0.9%) and glucose 50 mg/ml (5%) solution for infusion.

If rocuronium bromide is administered via the same infusion line with other medicinal products, it is important that the infusion line is adequately flushed (e.g. with sodium chloride 9 mg/ml (0.9 %) solution for infusion) between administration of rocuronium bromide and medicinal products for which incompatibility with rocuronium bromide has been demonstrated or for which compatibility with rocuronium bromide has not been established.

Any unused product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

[To be completed nationally.]

## **8. MARKETING AUTHORISATION NUMBER(S)**

[To be completed nationally.]

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

<{DD/MM/YYYY}> <{DD month YYYY}>

[To be completed nationally.]

## **10. DATE OF REVISION OF THE TEXT**

May 2011

*Date of SmPC: May 2011*